AVBP

Business Context and Reporting Period

Arrivent Biopharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on identifying, licensing, and globalizing biopharma innovations, primarily for oncology. The company's lead candidate is firmonertinib, a third-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC). This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as an emerging growth company and has not yet generated any product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $21.1 million (33%) compared to Q1 2025, primarily driven by a $23.7 million decrease in R&D expenses.
• R&D Expense Shift: The decrease in R&D was largely due to a $28.7 million reduction in early-stage program costs, which included a one-time $40 million upfront payment to a collaboration partner (Lepu) in Q1 2025. This was partially offset by a $4.2 million increase in personnel-related costs and a $0.8 million increase in costs for the lead candidate, firmonertinib.
• G&A Increase: General and administrative expenses increased by $3.0 million, attributed mainly to higher personnel-related costs.
• Financing Activity: The company raised $54.7 million net proceeds through its "at-the-market" (ATM) offering program in Q1 2026, compared to $6.5 million in the prior year period.
• Milestone Payments: The company incurred a $6.0 million developmental milestone payment to Lepu Biopharma during Q1 2026.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes that cash, cash equivalents, and marketable securities totaling $326.4 million as of March 31, 2026, are sufficient to fund operations for at least the next 12 months.
• Capital Needs: The company anticipates incurring additional losses until product candidates are approved and commercialized. Future funding will likely require additional equity or debt financings, collaborations, or licensing arrangements.
• Debt Facility: A $75 million term loan facility with Silicon Valley Bank is available but undrawn as of March 31, 2026. An amendment in March 2026 eliminated a condition for the second tranche.
• Development Progress:
  • Firmonertinib: Pivotal Phase 3 trials are ongoing for first-line NSCLC patients with exon 20 insertion and PACC mutations. Breakthrough Therapy Designation was received for exon 20 insertion in October 2023.
  • ARR-217: Phase 1 trial initiated in March 2026 for solid tumors.
  • ARR-002: US IND clearance received; Phase 1 trial expected to initiate in the second half of 2026.
• Risks: Key risks include the inability to raise additional capital, failure of clinical trials, regulatory delays, and intense competition in the oncology space (e.g., from AstraZeneca, Johnson & Johnson, and others). The company has no approved products and no revenue.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $326.4 million liquidity position against projected burn rates, especially given the $448 million accumulated deficit.
• ATM Program Capacity: Confirm the remaining capacity of the ATM program ($66.9 million as of March 31, 2026) and the terms of the July 2025 public offering.
• Milestone Obligations: Review the contingent payment obligations under the Allist, Alphamab, Aarvik, and Lepu agreements, which total over $1 billion in potential future payments.
• Clinical Trial Timelines: Monitor the progress and data readouts of the pivotal Phase 3 trials for firmonertinib and the initiation of Phase 1 trials for ARR-217 and ARR-002.
• Debt Covenants: Assess the conditions required to draw on the $75 million Silicon Valley Bank facility and the impact of interest rate fluctuations on potential borrowing costs.